Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.Rachel O. Abelman, Aditya Bardia, Beverly Moy et al.|Journal of Clinical Oncology|2024Cited by 6